• Explore /
  • Poster
  • / ­­­­­Phase II trial of the MEK1/2 inhibitor selumetinib (AZD6244) in adults with neurofibromatosis type 1 (NF1) and inoperable plexiform neurofibromas (PNs).

­­­­­Phase II trial of the MEK1/2 inhibitor selumetinib (AZD6244) in adults with neurofibromatosis type 1 (NF1) and inoperable plexiform neurofibromas (PNs).

Abstract Poster

Authors

null

Diana Bradford

Children's National Medical Center, Washington, DC

Diana Bradford , Patricia Whitcomb , Eva Dombi , Alice P. Chen , Andrea Baldwin , Pamela Wolters , Staci Martin , John Glod , Joanne Derdak , Geraldine Helen O'Sullivan Coyne , Edward W. Cowen , Marielle Holmblad , Jane Trepel , Bradford J. Wood , Scott M. Paul , Wade Clapp , Gary L. Johnson , Larry Rubinstein , L. Austin Doyle , Brigitte C. Widemann

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2016 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Developmental Therapeutics—Clinical Pharmacology and Experimental Therapeutics

Track

Developmental Therapeutics and Translational Research

Sub Track

Other Novel Agents

Clinical Trial Registration Number

NCT02644512

Citation

J Clin Oncol 34, 2016 (suppl; abstr TPS2596)

DOI

10.1200/JCO.2016.34.15_suppl.TPS2596

Abstract #

TPS2596

Poster Bd #

293b

Abstract Disclosures

Similar Posters

First Author: Geraldine Helen O'Sullivan Coyne

Poster

2021 ASCO Annual Meeting

Phase II study of binimetinib with imatinib in patients with unresectable KIT-mutant melanoma.

Phase II study of binimetinib with imatinib in patients with unresectable KIT-mutant melanoma.

First Author: Katy K. Tsai

First Author: Brigitte C. Widemann

First Author: Graeme Currie